CIBC Private Wealth Group LLC Has $83.13 Million Position in Cencora, Inc. $COR

CIBC Private Wealth Group LLC lowered its holdings in Cencora, Inc. (NYSE:COR) by 12.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 266,003 shares of the company’s stock after selling 38,453 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Cencora were worth $83,134,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Cencora by 13.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after buying an additional 5,543 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Cencora during the third quarter worth $26,191,000. Mediolanum International Funds Ltd raised its stake in Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after acquiring an additional 32,138 shares in the last quarter. Chilton Investment Co. Inc. bought a new position in shares of Cencora during the third quarter valued at $459,000. Finally, Advisors Asset Management Inc. lifted its holdings in shares of Cencora by 40.3% during the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after acquiring an additional 4,973 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on COR shares. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Morgan Stanley set a $380.00 price target on shares of Cencora in a research report on Tuesday. Wells Fargo & Company upped their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Evercore reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $403.17.

Cencora Price Performance

Shares of COR stock opened at $325.50 on Thursday. The stock’s fifty day moving average is $355.15 and its 200-day moving average is $339.41. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The stock has a market capitalization of $63.32 billion, a PE ratio of 39.12, a PEG ratio of 1.56 and a beta of 0.68. Cencora, Inc. has a 52 week low of $262.73 and a 52 week high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same period last year, the company posted $3.73 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Insiders Place Their Bets

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 10,124 shares of company stock valued at $3,532,646. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.